Actively Recruiting
Phase 1a1b Study of LY4052031 with or without Pembrolizumab in Adults with Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Led by Eli Lilly and Company · Updated on 2026-11-04
460
Participants Needed
40
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying LY4052031, an antibody-drug conjugate targeting the protein nectin-4, in adults with advanced or metastatic solid tumors, including urothelial cancer. This Phase 1a1b trial aims to assess the safety, tolerability, and effectiveness of LY4052031 alone or combined with pembrolizumab. The study includes patients with various solid tumor types known to express nectin-4, exploring optimal dosing and treatment impact. The trial has two phases Phase 1a focuses on dose escalation and optimization of LY4052031 given intravenously to find the recommended dose for Phase 2. Phase 1b evaluates the efficacy and safety of LY4052031 at the selected dose, either alone or with pembrolizumab, across different tumor cohorts based on cancer type and treatment history. Participants receive study drugs through intravenous infusions during these phases. Participants undergo assessments including tumor measurements following RECIST v1.1 criteria, performance status evaluation, and collection of tumor tissue samples. The study monitors overall response rate and various measures of antitumor activity up to approximately four years. Safety and pharmacokinetics of LY4052031 are also evaluated throughout the trial. Participation may last up to about four years, with regular visits for treatment and monitoring.
CONDITIONS
Brief Title
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here